<DOC>
	<DOCNO>NCT01434290</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Given radiation therapy different way may kill tumor cell . PURPOSE : This randomized phase II trial study radiation therapy see well work treat patient prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To demonstrate 1-year health-related quality life ( HRQOL ) least one hypofractionated arm significantly low baseline measure Bowel Urinary domain Expanded Prostate Cancer Index Composite ( EPIC ) instrument . Secondary - To estimate degree change HRQOL arm Sexual Hormonal EPIC domains Utilization Sexual Medications/Devices baseline 1 year , 2 year , 5 year . - To estimate degree change global HRQOL arm measure Euro Quality Life , 5 dimension ( EQ-5D ) baseline 1 year , 2 year , 5 year . - To estimate rate acute late gastrointestinal ( GI ) genitourinary ( GU ) toxicity arm 1 , 2 , 5 year . - To estimate prostate-specific antigen ( PSA ) failure arm 1 , 2 , 5 year . - To estimate disease-free survival ( DFS ) arm 1 , 2 , 5 year . - To estimate Quality Adjusted Life Years arm 1 , 2 , 5 year use EQ-5D DFS . - To identify genetic marker associate normal tissue toxicity result radiotherapy . - To collect tumor tissue biomarker study . - To estimate EPIC bowel urinary HRQOL continuous variable . OUTLINE : This multicenter study . Patients stratify accord treatment techniques/machine ( linear accelerator-based treatment [ exclude cyberknife ] v cyberknife v proton ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo hypofractionated radiotherapy use intensity-modulated radiation therapy ( IMRT ) , cyberknife , proton twice week approximately 2½ week ( 36.25 Gy total ) . - Arm II : Patients undergo hypofractionated radiotherapy use IMRT , cyberknife , proton day , 5 day week , approximately 2½ week ( 51.6 Gy total ) . Patients may undergo blood tumor tissue collection correlative study . Patients may also complete Utilization Sexual Medications/Devices , European Questionnaire-5D , Bowel Urinary domain Expanded Prostate Cancer Index Composite ( EPIC ) questionnaires baseline 1 , 2 , 5 year completion radiation therapy . After completion study therapy , patient followed-up every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis adenocarcinoma prostate within 180 day randomization History/physical examination digital rectal examination prostate within 60 day prior registration Histological evaluation prostate biopsy assignment Gleason score biopsy material ; Gleason score 26 within 180 day randomization Clinical stage T12a ( AJCC 7th edition ) within 90 day randomization Prostatespecific antigen ( PSA ) &lt; 10 ng/mL within 60 day prior registration ; PSA obtain within 10 day prostate biopsy No evidence distant metastases No regional lymph node involvement PATIENT CHARACTERISTICS : Zubrod performance status 01 Willingness ability complete Expanded Prostate Cancer Index Composite ( EPIC ) questionnaire No prior concurrent invasive malignancy ( except nonmelanomatous skin cancer ) lymphomatous/hematogenous malignancy unless continually diseasefree minimum 5 year ( example , carcinoma oral cavity permissible ; however , patient prior history bladder cancer allow ) No severe , active comorbidity , define follow : Unstable angina and/or congestive heart failure require hospitalization within last 6 month Transmural myocardial infarction within last 6 month Acute bacterial fungal infection require intravenous antibiotic time registration Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration Hepatic insufficiency result clinical jaundice and/or coagulation defect Laboratory test liver function coagulation parameter require entry protocol Acquired Immune Deficiency Syndrome ( AIDS ) base upon current Center Disease Control ( CDC ) definition HIV testing require entry protocol Protocolspecific requirement may also exclude immunocompromised patient PRIOR CONCURRENT THERAPY : No prior radical surgery ( prostatectomy ) , cryosurgery , highintensity focus ultrasonography ( HIFU ) prostate cancer No prior pelvic irradiation , prostate brachytherapy , bilateral orchiectomy No prior hormonal therapy , luteinizing hormonereleasing hormone ( LHRH ) agonists ( e.g. , goserelin , leuprolide ) LHRH antagonist ( e.g. , degarelix ) , antiandrogens ( e.g. , flutamide , bicalutamide ) , estrogens ( e.g. , diethylstilbestrol ( DES ) ) , surgical castration ( orchiectomy ) No finasteride within 30 day prior registration Prostatespecific antigen ( PSA ) obtain prior 30 day stop finasteride No dutasteride within 90 day prior registration PSA obtain prior 90 day stop dutasteride No prior concurrent cytotoxic chemotherapy prostate cancer Patients Coumadin bloodthinning agent eligible study No concurrent 3Dconformal radiation therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>psychosocial effect cancer treatment</keyword>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>